SCHEDULE: RA Capital Adjusts VOR Biopharma Stake

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. following recent stock sales.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons"), have filed Amendment No. 14 to their Schedule 13D concerning VOR Biopharma Inc.
• As of April 7, 2026, the Reporting Persons collectively beneficially own 12,399,706 shares of common stock, representing 19.9% of the outstanding shares.
• This ownership includes shares held directly by the Fund, common stock warrants, and pre-funded warrants. The Fund is currently restricted from exercising certain warrants due to beneficial ownership blockers.
• The filing details open market sales of VOR Biopharma common stock by the Fund on April 2, 2026, and April 6, 2026.
• The total number of outstanding shares of common stock as of March 30, 2026, was reported as 54,185,582.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on ownership adjustments and regulatory compliance rather than new strategic initiatives or financial performance.

Negatives

• The Fund has engaged in open market sales of VOR Biopharma stock, indicating a reduction in their stake during the reporting period.

Risks

• The Common Stock Warrants contain a beneficial ownership blocker that prevents exercise if ownership exceeds 9.99%.
• The Pre-Funded Warrants contain a beneficial ownership blocker that prevents exercise if ownership exceeds 19.99% or results in beneficial ownership of more than 12,399,706 shares.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It primarily reports on the current beneficial ownership and recent transactions by RA Capital Management and its affiliates.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes by institutional investors. RA Capital Management is a prominent life sciences-focused investment firm, and their filings often signal strategic shifts or active engagement with portfolio companies.

Stakeholder Impact

• Shareholders: Changes in beneficial ownership by a significant investor like RA Capital can influence market perception and potentially impact share price. The reported sales may suggest a reduction in conviction or a rebalancing of the portfolio.
• Company Management: Increased scrutiny from significant shareholders can influence corporate strategy and governance decisions.

Next Steps

• The Reporting Persons will continue to monitor the Issuer's business and may engage in further transactions or discussions regarding the Issuer's business, strategy, or prospects.

Key Dates

Recommendation

This filing is primarily an update on beneficial ownership and recent stock sales by a significant investor. It does not provide new financial performance data or strategic guidance from VOR Biopharma itself. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's operational and financial progress.

Keywords

Schedule 13D, RA Capital Management, VOR Biopharma, Beneficial Ownership, Stock Warrants, Pre-funded Warrants, SEC Filing, Amendment, Open Market Sale